{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:39:08Z","timestamp":1789749548172,"version":"4.0.1"},"reference-count":41,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,2,1]]},"abstract":"<jats:sec>\n                    <jats:title>CONTEXT:<\/jats:title>\n                    <jats:p>Infantile hemangiomas (IH) may be associated with significant functional impact.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>The objective of this study was to meta-analyze studies of pharmacologic interventions for children with IH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SOURCES:<\/jats:title>\n                    <jats:p>Data sources were Medline and other databases from 1982 to June 2015.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY SELECTION:<\/jats:title>\n                    <jats:p>Two reviewers assessed studies using predetermined inclusion criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA EXTRACTION:<\/jats:title>\n                    <jats:p>One reviewer extracted data with review by a second.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>We included 18 studies in a network meta-analysis assessing relative expected rates of IH clearance associated with \u03b2-blockers and steroids. Oral propranolol had the largest mean estimate of expected clearance (95%; 95% Bayesian credible interval [BCI]: 88%\u201399%) relative to oral corticosteroids (43%, 95% BCI: 21%\u201366%) and control (6%, 95% BCI: 1%\u201311%). Strength of evidence (SOE) was high for propranolol\u2019s effects on reducing lesion size compared with observation\/placebo. Corticosteroids demonstrated moderate effectiveness at reducing size\/volume (moderate SOE for improvement in IH). SOE was low for effects of topical timolol versus placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>LIMITATIONS:<\/jats:title>\n                    <jats:p>Methodologic limitations of available evidence may compromise SOE. Validity of meta-analytic estimates relies on the assumption of exchangeability among studies, conditional on effects of the intervention. Results rely on assumed lack of reporting bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Propranolol is effective at reducing IH size compared with placebo, observation, and other treatments including steroids in most studies. Corticosteroids demonstrate moderate effectiveness at reducing IH size\/volume. The meta-analysis estimates provide a relative ranking of anticipated rates of lesion clearance among treatments. Families and clinicians making treatment decisions should also factor in elements such as lesion size, location, number, and type, and patient and family preferences.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1542\/peds.2015-3896","type":"journal-article","created":{"date-parts":[[2016,1,15]],"date-time":"2016-01-15T20:53:39Z","timestamp":1452891219000},"source":"Crossref","is-referenced-by-count":71,"title":["Pharmacologic Interventions for Infantile Hemangioma: A Meta-analysis"],"prefix":"10.1542","volume":"137","author":[{"given":"Sivakumar","family":"Chinnadurai","sequence":"first","affiliation":[{"name":"Departments of Otolaryngology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Fonnesbeck","sequence":"additional","affiliation":[{"name":"Biostatistics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen M.","family":"Snyder","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology, Helen DeVos Children\u2019s Hospital, Grand Rapids, Michigan; and"},{"name":"Division of Pediatric Hematology\/Oncology, Monroe Carell Jr Children's Hospital at Vanderbilt, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nila A.","family":"Sathe","sequence":"additional","affiliation":[{"name":"Health Policy, and"},{"name":"Vanderbilt Evidence-Based Practice Center, Institute for Medicine and Public Health, Vanderbilt University Medical Center, Nashville, Tennessee;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Morad","sequence":"additional","affiliation":[{"name":"Pediatrics, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances E.","family":"Likis","sequence":"additional","affiliation":[{"name":"Vanderbilt Evidence-Based Practice Center, Institute for Medicine and Public Health, Vanderbilt University Medical Center, Nashville, Tennessee;"},{"name":"Vanderbilt University School of Nursing, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa L.","family":"McPheeters","sequence":"additional","affiliation":[{"name":"Health Policy, and"},{"name":"Vanderbilt Evidence-Based Practice Center, Institute for Medicine and Public Health, Vanderbilt University Medical Center, Nashville, Tennessee;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2016,2,1]]},"reference":[{"issue":"2","key":"2021120907175506700_B1","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1525-1470.2008.00626.x","article-title":"Infantile hemangiomas: how common are they? A systematic review of the medical literature.","volume":"25","author":"Kilcline","year":"2008","journal-title":"Pediatr Dermatol"},{"issue":"44","key":"2021120907175506700_B2","first-page":"2455","article-title":"Prevalence and characteristics of haemangiomas in young children [in Dutch]","volume":"149","author":"Hoornweg","year":"2005","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"2","key":"2021120907175506700_B3","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1542\/peds.58.2.218","article-title":"The incidence of birthmarks in the neonate.","volume":"58","author":"Jacobs","year":"1976","journal-title":"Pediatrics"},{"issue":"4","key":"2021120907175506700_B4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1525-1470.1993.tb00393.x","article-title":"The current management of vascular birthmarks.","volume":"10","author":"Enjolras","year":"1993","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"2021120907175506700_B5","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1542\/peds.2007-2767","article-title":"Growth characteristics of infantile hemangiomas: implications for management.","volume":"122","author":"Chang","year":"2008","journal-title":"Pediatrics"},{"issue":"1","key":"2021120907175506700_B6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.0736-8046.2004.21101.x","article-title":"Periocular hemangiomas: what every physician should know.","volume":"21","author":"Ceisler","year":"2004","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"2021120907175506700_B7","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1067\/mjd.2001.112382","article-title":"Ulcerated hemangiomas: clinical characteristics and response to therapy.","volume":"44","author":"Kim","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"2021120907175506700_B8","author":"Chamlin","year":"2007"},{"issue":"3","key":"2021120907175506700_B9","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2008-3458","article-title":"Propranolol for severe infantile hemangiomas: follow-up report.","volume":"124","author":"Sans","year":"2009","journal-title":"Pediatrics"},{"issue":"2","key":"2021120907175506700_B10","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2010-0029","article-title":"A randomized controlled trial of propranolol for infantile hemangiomas.","volume":"128","author":"Hogeling","year":"2011","journal-title":"Pediatrics"},{"issue":"10","key":"2021120907175506700_B11","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1111\/j.1651-2227.2012.02783.x","article-title":"Propranolol treatment for severe infantile hemangiomas: a single-centre 3-year experience.","volume":"101","author":"Georgountzou","year":"2012","journal-title":"Acta Paediatr"},{"issue":"24","key":"2021120907175506700_B12","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1056\/NEJMc0708819","article-title":"Propranolol for severe hemangiomas of infancy.","volume":"358","author":"L\u00e9aut\u00e9-Labr\u00e8ze","year":"2008","journal-title":"N Engl J Med"},{"key":"2021120907175506700_B13","unstructured":"Agency for Healthcare Research and Quality . Effective Health Care Program. Strategies to Treat and Manage Infantile Hemangioma: Research Protocol. Available at: http:\/\/www.effectivehealthcare.ahrq.gov\/search-for-guides-reviews-and-reports\/?pageaction=displayproduct&productID=2016. Accessed December 9, 2015"},{"key":"2021120907175506700_B14","doi-asserted-by":"crossref","DOI":"10.1201\/b16018","volume-title":"Bayesian Data Analysis","author":"Gelman","year":"2013","edition":"3rd ed."},{"issue":"8","key":"2021120907175506700_B15","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa1404710","article-title":"A randomized, controlled trial of oral propranolol in infantile hemangioma.","volume":"372","author":"L\u00e9aut\u00e9-Labr\u00e8ze","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"2021120907175506700_B16","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/MPH.0b013e3182a11658","article-title":"Propranolol for infantile hemangioma (PINCH): an open-label trial to assess the efficacy of propranolol for treating infantile hemangiomas and for determining the decline in heart rate to predict response to propranolol.","volume":"35","author":"Sondhi","year":"2013","journal-title":"J Pediatr Hematol Oncol"},{"issue":"1","key":"2021120907175506700_B17","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/bjd.12217","article-title":"Double-blind randomized pilot trial evaluating the efficacy of oral propranolol on infantile haemangiomas in infants &lt; 4 months of age.","volume":"169","author":"L\u00e9aut\u00e9-Labr\u00e8ze","year":"2013","journal-title":"Br J Dermatol"},{"issue":"5","key":"2021120907175506700_B18","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1684\/ejd.2013.2146","article-title":"Propranolol and infantile hemangiomas: different routes of administration, a randomized clinical trial.","volume":"23","author":"Zaher","year":"2013","journal-title":"Eur J Dermatol"},{"issue":"4","key":"2021120907175506700_B19","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1001\/jamaoto.2013.6723","article-title":"Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: a randomized clinical trial.","volume":"140","author":"Bauman","year":"2014","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"6","key":"2021120907175506700_B20","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1525-1470.2011.01551.x","article-title":"Propranolol versus prednisone in the treatment of infantile hemangiomas: a retrospective comparative study.","volume":"28","author":"Bertrand","year":"2011","journal-title":"Pediatr Dermatol"},{"issue":"12","key":"2021120907175506700_B21","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1001\/archdermatol.2011.203","article-title":"Propranolol vs corticosteroids for infantile hemangiomas: a multicenter retrospective analysis.","volume":"147","author":"Price","year":"2011","journal-title":"Arch Dermatol"},{"issue":"12","key":"2021120907175506700_B22","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/j.jpedsurg.2013.08.020","article-title":"Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: a randomized controlled study.","volume":"48","author":"Malik","year":"2013","journal-title":"J Pediatr Surg"},{"issue":"4","key":"2021120907175506700_B23","doi-asserted-by":"crossref","first-page":"733e","DOI":"10.1097\/PRS.0b013e318245e739","article-title":"Comparison of efficacy of intralesional bleomycin and oral propanolol in management of hemangiomas.","volume":"129","author":"Thayal","year":"2012","journal-title":"Plast Reconstr Surg"},{"issue":"1","key":"2021120907175506700_B24","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1365-2133.2012.11131.x","article-title":"Expanding the therapeutic repertoire of infantile haemangiomas: cohort-blinded study of oral nadolol compared with propranolol.","volume":"168","author":"Pope","year":"2013","journal-title":"Br J Dermatol"},{"issue":"6","key":"2021120907175506700_B25","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jaad.2014.01.905","article-title":"Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study.","volume":"70","author":"\u00c1barz\u00faa-Araya","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2021120907175506700_B26","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3892\/etm.2013.1176","article-title":"Treatment of superficial infantile hemangiomas with timolol: evaluation of short-term efficacy and safety in infants.","volume":"6","author":"Yu","year":"2013","journal-title":"Exp Ther Med"},{"key":"2021120907175506700_B27","author":"Chan","year":"2013"},{"issue":"8","key":"2021120907175506700_B28","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/ced.12150","article-title":"Imiquimod 5% cream versus timolol 0.5% ophthalmic solution for treating superficial proliferating infantile haemangiomas: a retrospective study.","volume":"38","author":"Qiu","year":"2013","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"2021120907175506700_B29","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3109\/09546634.2014.990412","article-title":"Topical timolol maleate 0.5% for infantile hemangioma; its effectiveness and\/or adjunctive pulsed dye laser\u2014single center experience of 102 cases in Korea.","volume":"26","author":"Park","year":"2015","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"2021120907175506700_B30","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/pde.12542","article-title":"Topical timolol solution versus laser in treatment of infantile hemangioma: a comparative study.","volume":"32","author":"Tawfik","year":"2015","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"2021120907175506700_B31","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2006-2962","article-title":"Oral versus high-dose pulse corticosteroids for problematic infantile hemangiomas: a randomized, controlled trial.","volume":"119","author":"Pope","year":"2007","journal-title":"Pediatrics"},{"issue":"10","key":"2021120907175506700_B32","first-page":"662","article-title":"Corticosteroids therapy in the management of infantile cutaneous hemangiomas.","volume":"16","author":"Jalil","year":"2006","journal-title":"J Coll Physicians Surg Pak"},{"key":"2021120907175506700_B33","volume-title":"Assessing the Risk of Bias of Individual Studies in Systematic Reviews of Health Care Interventions","author":"Viswanathan","year":"2008"},{"key":"2021120907175506700_B34","unstructured":"Wells\u2008G, O\u2019Connell\u2008D, Peterson\u2008J, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed December 9, 2015"},{"key":"2021120907175506700_B35","volume-title":"McMaster Quality Assessment Scale of Harms (McHarm) for Primary Studies","author":"McMaster University Centre for Evidence-based Practice","year":"2008"},{"key":"2021120907175506700_B36","unstructured":"Agency for Healthcare Research and Quality. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. AHRQ Publication No. 10(11)-EHC063-EF. Rockville, MD: Agency for Healthcare Research and Quality. March 2011. Available at: http:\/\/www.effectivehealthcare.ahrq.gov. Accessed December 9, 2015"},{"issue":"11","key":"2021120907175506700_B37","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.jclinepi.2014.11.023","article-title":"Grading the strength of a body of evidence when assessing health care interventions: an EPC update.","volume":"68","author":"Berkman","year":"2015","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"2021120907175506700_B38","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/PRS.0b013e31827c6fab","article-title":"Propranolol versus corticosteroids in the treatment of infantile hemangioma: a systematic review and meta-analysis.","volume":"131","author":"Izadpanah","year":"2013","journal-title":"Plast Reconstr Surg"},{"issue":"1","key":"2021120907175506700_B39","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/bcp.12235","article-title":"The effectiveness of propranolol in treating infantile haemangiomas: a meta-analysis including 35 studies.","volume":"78","author":"Lou","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"2021120907175506700_B40","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s13312-013-0098-9","article-title":"Propranolol therapy for infantile hemangioma.","volume":"50","author":"Gunturi","year":"2013","journal-title":"Indian Pediatr"},{"issue":"2","key":"2021120907175506700_B41","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/pde.12089","article-title":"Propranolol and infantile hemangiomas four years later: a systematic review.","volume":"30","author":"Marqueling","year":"2013","journal-title":"Pediatr Dermatol"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2015-3896\/1093586\/peds_20153896.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2015-3896\/1093586\/peds_20153896.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T15:48:55Z","timestamp":1654098535000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/137\/2\/e20153896\/52774\/Pharmacologic-Interventions-for-Infantile"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,1]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,2,1]]},"published-print":{"date-parts":[[2016,2,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2015-3896","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,1]]},"article-number":"e20153896"}}